Hancock Jaffe Laboratories HJLI
At closeOct 1, 2021, 12:00 AM EDT
- Market cap
- 98.26M
- EPS (ttm)
- -2.71
- Shares out
- 9.47M
- Forward P/E
- -9.98
- Volume
- 221.87K
- Avg volume
- 777.48K
- Open
- 10.71
- Previous close
- 10.38
- Day's range
- 10.26 – 10.74
- 52-week range
- 4.99 – 17.68
- Beta
- 1.54
- Analysts
- Strong Buy
- Price target
- 26.00 (+150.5%)
- Earnings date
- Nov 16, 2021
5m +0.08 (+1.16%)
Key statistics
- Enterprise value
- 48.06M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.56M
- Total cash
- 41.04M
- Total debt
- 723.55K
- Return on equity
- -55.76%
- Short % of float
- 8.37%
- 50-day average
- 9.02
- 200-day average
- 6.95
Analyst view
Consensus: strong buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 16, 2021
Expected Nov 16, 2021. Consensus EPS estimate -0.34.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 12, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Nov 17, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- hancockjaffe.com
News
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann 
Hancock Jaffe To Rebrand As enVVeno Medical 
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021 
Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics 
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules 
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve 
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting 
HJLI Stock Price Increases Over 35% Pre-Market: Why It Happened 
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve 
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Your note
Sign in to keep a note on HJLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIODYNE HOLDING, S.A. | Unknown | Sale | Aug 20, 2020 | 1,405,430 |
| BROENNIMANN BENEDICT | Officer | Stock Award(Grant) | Nov 26, 2018 | 0 |
| DUHAY FRANCIS | Director | Stock Award(Grant) | Jul 16, 2020 | 107,228 |
| GRAY ROBERT | Director | Stock Award(Grant) | Jul 16, 2020 | 78,250 |
| JENUSAITIS MATTHEW | Director | Stock Award(Grant) | Jul 16, 2020 | 62,500 |
| SHRIVASTAVA SANJAY | Director | Stock Award(Grant) | Jul 16, 2020 | 97,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 3.99% | 346,885 | 2.38M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 2.98% | 258,680 | 1.78M | Jun 29, 2021 |
| Worth Venture Partners, LLC | 0.95% | 82,886 | 569.43K | Jun 29, 2021 |
| Kepos Capital Lp | 0.82% | 71,428 | 490.71K | Jun 29, 2021 |
| Geode Capital Management, LLC | 0.73% | 63,753 | 437.98K | Jun 29, 2021 |
| Blackrock Inc. | 0.26% | 22,430 | 154.09K | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.74% | 151,150 | 1.04M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 1.21% | 104,806 | 720.02K | Jun 29, 2021 |
| Fidelity Extended Market Index Fund | 0.47% | 40,672 | 250.54K | Jul 30, 2021 |
| iShares Micro Cap ETF | 0.23% | 20,366 | 160.48K | Aug 30, 2021 |
| Fidelity Total Market Index Fund | 0.12% | 10,208 | 62.88K | Jul 30, 2021 |
| Fidelity Series Total Market Index Fund | 0.07% | 5,882 | 36.23K | Jul 30, 2021 |